Feed API
Signals via API
Feed API access for integrations is available under Business plans. Public endpoints show a limited or redacted payload; Pro is for individual app access.
Public sample from the feed endpoint. The backend exposes read endpoints for signals, storylines, and briefings.
Public sample
GET /v1/feed/stories?limit=3&timeframe=24h&sort=momentum&tenant=biotech
{
"run_id": "20e10bee-5127-426d-ad17-b429b6a048ca",
"timeframe": "24h",
"items": [
{
"type": "storyline",
"id": "5877e6bf-89ac-45a4-bb68-a1d62a44a453",
"story_id": "5877e6bf-89ac-45a4-bb68-a1d62a44a453",
"run_id": "20e10bee-5127-426d-ad17-b429b6a048ca",
"snapshot_id": "f24360d0-2f45-4e6c-a452-156301e85592",
"narrative_id": "abca3e27-7173-45d2-9b4a-a6c0f2846220",
"first_seen": "2026-10-12T17:02:55.213674+00:00",
"last_seen": "2026-10-13T05:05:22.409054+00:00",
"first_seen_at": "2026-10-12T13:35:02+00:00",
"last_seen_at": "2026-10-12T13:40:00+00:00",
"status": "open",
"title": "Agenda of the CHMP meeting 12-15 October 2026",
"summary": "Agenda of the CHMP meeting 12-15 October 2026",
"top_tickers": [],
"why_now": [],
"metrics": {
"score_total": 0.796216,
"momentum_24h": 3,
"post_count": 3,
"unique_origin_publishers": 1,
"unique_publisher_types": 1,
"origin_share_top1": 1,
"amplifier_share_top1": null,
"duplicate_ratio": 0,
"evidence_score": 0.25,
"source_types_count": 1,
"unique_origin_domains": 1,
"unique_publishers": 1,
"quality_policy_version": 6,
"tenant_claim_coherence_policy_version": 3
},
"trend_status": "insufficient_history",
"trend_sparkline": "▁▁",
"trend_points_n": 2,
"trend_window": {
"lookback_days": 14,
"max_points": 36,
"value_key": "score_total"
},
"maturity_label": "seed",
"maturity_score": 0.23586791666666668,
"top_sources": [
{
"label": "EMA (via EMA What's new): Committee for Medicinal Products for Human Use (CHMP): 12-15 October 2026, European Medicines Agency, Amsterdam, the Netherlands, from 12 October 2026 to 15 ...",
"source_type": "rss",
"evidence_class": "primary",
"provenance_role": "origin",
"publisher_subtype": "regulator"
}
],
"rank_story": 0.7948022847997827,
"p_score": 1,
"p_mom": 1,
"recency": 0.9792091391991307,
"risk_penalty": 0.1,
"badges": [
"seed",
"insufficient_history",
"low_evidence"
],
"storyline_category": "narrative",
"storyline_category_reason": "multi_run_continuity",
"verified_update_issuer_count": 1,
"storyline_independent_origin_count": 1,
"storyline_continuity_points": 2,
"sources": [],
"llm_title": "EMA publishes materials for October 2026 CHMP meeting",
"llm_summary": "The European Medicines Agency has published an agenda, annex and event listing for the Committee for Medicinal Products for Human Use meeting scheduled for 12–15 October 2026. The materials do not report any resulting opinions or approvals.",
"llm_narrative_frame": "EMA has published the agenda, annex and event listing for the Committee for Medicinal Products for Human Use meeting scheduled for 12–15 October 2026. The materials establish the meeting framework but do not indicate any resulting regulatory opinions or approvals.",
"llm_narrative_label": "EMA regulatory agenda",
"llm_narrative_type": "one_off_news",
"llm_why_now": [
"The meeting is scheduled for 12–15 October 2026.",
"EMA has published the agenda, annex and event listing."
],
"llm_why_it_matters": [
"The materials outline the published framework for an upcoming human-medicines committee meeting.",
"They distinguish meeting planning from subsequent regulatory opinions or approvals."
],
"llm_top_sources": [
{
"label": "CHMP meeting event, 12–15 October 2026"
},
{
"label": "Draft CHMP agenda, 12–15 October 2026"
},
{
"label": "Annex to draft CHMP agenda"
}
],
"entities": {
"projects": [
"CHMP meeting"
]
},
"recurring_claims": [
{
"claim": "EMA published agenda materials and an event listing for the CHMP meeting scheduled for 12–15 October 2026.",
"evidence_urls": [
"https://ema.europa.eu/en/events/committee-medicinal-products-human-use-chmp-12-15-october-2026",
"https://ema.europa.eu/system/files/documents/agenda/draft-chmp-agenda-12-15-october-2026-rev2_en.pdf",
"https://ema.europa.eu/system/files/documents/agenda/drat-chmp-annex-agenda-12-15-october-2026-rev2_en.xlsx"
]
}
],
"stance_map": [
{
"who": "European Medicines Agency",
"stance": "neutral",
"evidence_urls": [
"https://ema.europa.eu/en/events/committee-medicinal-products-human-use-chmp-12-15-october-2026",
"https://ema.europa.eu/system/files/documents/agenda/draft-chmp-agenda-12-15-october-2026-rev2_en.pdf",
"https://ema.europa.eu/system/files/documents/agenda/drat-chmp-annex-agenda-12-15-october-2026-rev2_en.xlsx"
]
}
],
"quality_flags": {
"mixed_topic_risk": "low",
"promo_risk": "low",
"source_quality": "high"
},
"editor_note": "The supplied posts document meeting materials only; they do not report CHMP opinions or approvals.",
"scope_tags": [
"regulatory",
"EMA",
"CHMP",
"drug development"
],
"scope_tags_raw": [
"regulatory",
"EMA",
"CHMP",
"drug development"
],
"llm_status": "accepted",
"llm_meta": {
"model": "gpt-5.6-luna",
"prompt_version": "enrich_v3",
"input_hash": "f46b3b1871ec6d48d1ce8a3a783221f6a131bcf703d80490f741cd708c5b371a",
"updated_at": "2026-10-13T05:06:58.830965+00:00",
"llm_metadata": {
"env": "prod",
"host": "c9c536f11bab",
"stage": "signals.enrich",
"run_id": "20e10bee-5127-426d-ad17-b429b6a048ca",
"tenant": "biotech",
"service": "api",
"pipeline": "pipeline_run",
"correlation_id": "abca3e27-7173-45d2-9b4a-a6c0f2846220"
}
},
"display_title": "EMA publishes materials for October 2026 CHMP meeting",
"display_summary": "The European Medicines Agency has published an agenda, annex and event listing for the Committee for Medicinal Products for Human Use meeting scheduled for 12–15 October 2026. The materials do not report any resulting opinions or approvals.",
"display_tags": [
"regulatory",
"ema",
"chmp",
"drug_development"
],
"tags": [
"regulatory",
"ema",
"chmp",
"drug_development"
],
"cscope_tags": [
"regulatory",
"ema",
"chmp",
"drug_development"
],
"display_why_now": [
"The meeting is scheduled for 12–15 October 2026.",
"EMA has published the agenda, annex and event listing."
],
"display_why_it_matters": [
"The materials outline the published framework for an upcoming human-medicines committee meeting.",
"They distinguish meeting planning from subsequent regulatory opinions or approvals."
],
"why_now_display": [
"The meeting is scheduled for 12–15 October 2026.",
"EMA has published the agenda, annex and event listing."
],
"why_it_matters_display": [
"The materials outline the published framework for an upcoming human-medicines committee meeting.",
"They distinguish meeting planning from subsequent regulatory opinions or approvals."
],
"show_why": true,
"sources_display": [
{
"label": "ema.europa.eu: CHMP meeting event, 12–15 October 2026"
}
],
"editor_status": "passed",
"fields_replaced": [],
"narrative_frame_display": "EMA has published the agenda, annex and event listing for the Committee for Medicinal Products for Human Use meeting scheduled for 12–15 October 2026. The materials establish the meeting framework but do not indicate any resulting regulatory opinions or approvals.",
"display_rank_base_score": 3,
"display_rank_score": 1000000003,
"display_rank_boost": 1000000000,
"lane": "chatter",
"lane_reason": "maturity=seed",
"evidence_mix": {
"primary": 1,
"secondary": 0,
"specialist": 0,
"aggregator": 0,
"social": 0
},
"sourceStats": {
"qualityPolicyVersion": 6,
"evidenceDocumentCount": 3,
"uniqueItemCount": 3,
"uniquePublisherCount": 1,
"uniqueCanonicalOriginCount": 1,
"independentNonSocialCount": 1,
"primaryCount": 1,
"secondaryCount": 0,
"uniqueDomainsCount": 1,
"aggregatorCount": 0,
"socialCount": 0,
"sourceTypeDiversityCount": 1,
"topSourceShare": 1,
"passesTopSignalsGate": false,
"gateReason": "independentNonSocial=1; primary=1; secondary=0; documents=3; publishers=1; canonicalOrigins=1; topSourceShare=1.0; rule=>=2 unique canonical primary/secondary publishers; aggregators/social excluded"
},
"evidence_meta": {
"post_count": 3,
"unique_origin_publishers": 1,
"source_types_count": 1,
"origin_share_top1": 1
},
"gate": {
"passesTopSignalsGate": false,
"gateReason": "independentNonSocial=1; primary=1; secondary=0; documents=3; publishers=1; canonicalOrigins=1; topSourceShare=1.0; rule=>=2 unique canonical primary/secondary publishers; aggregators/social excluded"
},
"tenant_claim_coherence": {
"tenant": "biotech",
"status": "not_applicable",
"claim_scope": "not_applicable",
"reason_codes": [],
"public_anchors": {},
"evidence_anchors": {},
"debug": {
"evidence_record_count": 3,
"matching_record_count": 0,
"independent_support_count": 0,
"conflicting_record_count": 0
}
},
"evidence_quality_flag": "weak"
},
{
"type": "storyline",
"id": "c4aa8baa-7d9d-4045-8f7e-a78969fa41bb",
"story_id": "c4aa8baa-7d9d-4045-8f7e-a78969fa41bb",
"run_id": "20e10bee-5127-426d-ad17-b429b6a048ca",
"snapshot_id": "3f0e45f5-31df-4c76-acc1-c1e35f380869",
"narrative_id": "a50e35e0-6762-44ba-8347-d86c25cd9913",
"first_seen": "2026-10-12T17:02:55.213674+00:00",
"last_seen": "2026-10-13T05:05:22.409054+00:00",
"first_seen_at": "2026-10-12T11:05:58+00:00",
"last_seen_at": "2026-10-12T13:45:58+00:00",
"status": "open",
"title": "BMS eyes filings for idiopathic pulmonary fibrosis drug",
"summary": "BMS eyes filings for idiopathic pulmonary fibrosis drug Phil.Taylor Mon, 12/10/2026 - 13:45",
"top_tickers": [],
"why_now": [],
"metrics": {
"score_total": 0.474243,
"momentum_24h": 2,
"post_count": 2,
"unique_origin_publishers": 1,
"unique_publisher_types": 1,
"origin_share_top1": 1,
"amplifier_share_top1": 1,
"duplicate_ratio": 0,
"evidence_score": 0.25,
"source_types_count": 1,
"unique_origin_domains": 1,
"unique_publishers": 1,
"quality_policy_version": 6,
"tenant_claim_coherence_policy_version": 3
},
"trend_status": "insufficient_history",
"trend_sparkline": "▁█",
"trend_points_n": 2,
"trend_window": {
"lookback_days": 14,
"max_points": 36,
"value_key": "score_total"
},
"maturity_label": "chatter",
"maturity_score": 0.2729316666666667,
"top_sources": [
{
"label": "Pharmaphorum: BMS eyes filings for idiopathic pulmonary fibrosis drug",
"source_type": "rss",
"evidence_class": "secondary",
"provenance_role": "origin",
"publisher_subtype": "media"
}
],
"rank_story": -0.15519771520021736,
"p_score": 0,
"p_mom": 0,
"recency": 0.9792091391991307,
"risk_penalty": 0.2,
"badges": [
"chatter",
"insufficient_history",
"low_evidence"
],
"storyline_category": "narrative",
"storyline_category_reason": "multi_run_continuity",
"verified_update_issuer_count": 0,
"storyline_independent_origin_count": 1,
"storyline_continuity_points": 2,
"sources": [],
"llm_title": "Contrasting signals emerge for two drug-development programs",
"llm_summary": "Reports on two separate drug-development programs provide contrasting signals: potential filings for a Bristol Myers Squibb idiopathic pulmonary fibrosis drug and data that undercut the potential of MSD's eye drug remigromig.",
"llm_narrative_frame": "A mixed drug-development update: Bristol Myers Squibb is considering filings for an idiopathic pulmonary fibrosis drug, while MSD data appear to weaken the potential of its eye drug remigromig.",
"llm_narrative_label": "Drug-development updates",
"llm_narrative_type": "narrative",
"llm_why_now": [
"Both reports were published in the same news cycle.",
"Together they provide a snapshot of current development signals for two programs."
],
"llm_why_it_matters": [
"The reports show divergent development signals across two drug programs.",
"One update concerns potential filings, while the other raises questions about a drug's prospects."
],
"llm_top_sources": [
{
"label": "BMS eyes filings for idiopathic pulmonary fibrosis drug"
},
{
"label": "MSD data reveal undercuts eye drug remigromig's potential"
}
],
"entities": {
"projects": [
"Idiopathic pulmonary fibrosis drug",
"Remigromig"
],
"companies": [
"Bristol Myers Squibb",
"MSD"
],
"people": [
"Phil Taylor"
]
},
"recurring_claims": [
{
"claim": "Bristol Myers Squibb is considering filings for an idiopathic pulmonary fibrosis drug.",
"evidence_urls": [
"https://pharmaphorum.com/news/bms-eyes-filings-idiopathic-pulmonary-fibrosis-drug"
]
},
{
"claim": "MSD data appear to weaken the potential of the eye drug remigromig.",
"evidence_urls": [
"https://pharmaphorum.com/news/msd-data-reveal-undercuts-eye-drug-remigromigs-potential"
]
}
],
"stance_map": [
{
"who": "Pharmaphorum on Bristol Myers Squibb",
"stance": "neutral",
"evidence_urls": [
"https://pharmaphorum.com/news/bms-eyes-filings-idiopathic-pulmonary-fibrosis-drug"
]
},
{
"who": "Pharmaphorum on MSD's remigromig",
"stance": "questions",
"evidence_urls": [
"https://pharmaphorum.com/news/msd-data-reveal-undercuts-eye-drug-remigromigs-potential"
]
}
],
"quality_flags": {
"mixed_topic_risk": "low",
"promo_risk": "low",
"source_quality": "medium"
},
"editor_note": "Two same-day reports present contrasting signals for separate drug-development programs.",
"scope_tags": [
"drug_development",
"clinical_research",
"biotech"
],
"scope_tags_raw": [
"drug_development",
"clinical_research",
"biotech"
],
"llm_status": "accepted",
"llm_meta": {
"model": "gpt-5.6-luna",
"prompt_version": "enrich_v3",
"input_hash": "7de549ba0fc841560689c4de5f52fc9be71eed43f12a479879649d0b65ab76de",
"updated_at": "2026-10-13T05:06:58.847583+00:00",
"llm_metadata": {
"env": "prod",
"host": "c9c536f11bab",
"stage": "signals.enrich",
"run_id": "20e10bee-5127-426d-ad17-b429b6a048ca",
"tenant": "biotech",
"service": "api",
"pipeline": "pipeline_run",
"correlation_id": "a50e35e0-6762-44ba-8347-d86c25cd9913"
}
},
"display_title": "Contrasting signals emerge for two drug-development programs",
"display_summary": "Reports on two separate drug-development programs provide contrasting signals: potential filings for a Bristol Myers Squibb idiopathic pulmonary fibrosis drug and data that undercut the potential of MSD's eye drug remigromig.",
"display_tags": [
"drug_development",
"clinical_research",
"biotech"
],
"tags": [
"drug_development",
"clinical_research",
"biotech"
],
"cscope_tags": [
"drug_development",
"clinical_research",
"biotech"
],
"display_why_now": [
"Both reports were published in the same news cycle.",
"Together they provide a snapshot of current development signals for two programs."
],
"display_why_it_matters": [
"The reports show divergent development signals across two drug programs.",
"One update concerns potential filings, while the other raises questions about a drug's prospects."
],
"why_now_display": [
"Both reports were published in the same news cycle.",
"Together they provide a snapshot of current development signals for two programs."
],
"why_it_matters_display": [
"The reports show divergent development signals across two drug programs.",
"One update concerns potential filings, while the other raises questions about a drug's prospects."
],
"show_why": true,
"sources_display": [
{
"label": "pharmaphorum.com: BMS eyes filings for idiopathic pulmonary fibrosis drug"
}
],
"editor_status": "passed",
"fields_replaced": [],
"narrative_frame_display": "A mixed drug-development update: Bristol Myers Squibb is considering filings for an idiopathic pulmonary fibrosis drug, while MSD data appear to weaken the potential of its eye drug remigromig.",
"display_rank_base_score": 2,
"display_rank_score": 1000000002,
"display_rank_boost": 1000000000,
"lane": "chatter",
"lane_reason": "maturity=chatter",
"evidence_mix": {
"primary": 0,
"secondary": 1,
"specialist": 0,
"aggregator": 0,
"social": 0
},
"sourceStats": {
"qualityPolicyVersion": 6,
"evidenceDocumentCount": 2,
"uniqueItemCount": 2,
"uniquePublisherCount": 1,
"uniqueCanonicalOriginCount": 1,
"independentNonSocialCount": 1,
"primaryCount": 0,
"secondaryCount": 1,
"uniqueDomainsCount": 1,
"aggregatorCount": 0,
"socialCount": 0,
"sourceTypeDiversityCount": 1,
"topSourceShare": 1,
"passesTopSignalsGate": false,
"gateReason": "independentNonSocial=1; primary=0; secondary=1; documents=2; publishers=1; canonicalOrigins=1; topSourceShare=1.0; rule=>=2 unique canonical primary/secondary publishers; aggregators/social excluded"
},
"evidence_meta": {
"post_count": 2,
"unique_origin_publishers": 1,
"source_types_count": 1,
"origin_share_top1": 1
},
"gate": {
"passesTopSignalsGate": false,
"gateReason": "independentNonSocial=1; primary=0; secondary=1; documents=2; publishers=1; canonicalOrigins=1; topSourceShare=1.0; rule=>=2 unique canonical primary/secondary publishers; aggregators/social excluded"
},
"tenant_claim_coherence": {
"tenant": "biotech",
"status": "not_applicable",
"claim_scope": "not_applicable",
"reason_codes": [],
"public_anchors": {},
"evidence_anchors": {
"product": [
"bms",
"phil"
]
},
"debug": {
"evidence_record_count": 2,
"matching_record_count": 0,
"independent_support_count": 0,
"conflicting_record_count": 0
}
},
"evidence_quality_flag": "weak"
}
],
"next_cursor": null,
"disclaimer": "No investment advice. Research signals and sources only. EarlyNarratives provides informational signals derived from public sources. It does not provide financial, legal, or tax advice."
}Capabilities
- Signals and storylines feed endpoints with filtering and rate limits
- Briefing delivery endpoints for integrations
- Evidence link payloads for auditability
Integrate in your workflow
- Route top stories into Slack or Teams for morning and evening desk updates.
- Sync storyline evidence into Notion, Airtable, or internal research trackers.
- Feed metrics into BI dashboards for momentum, concentration, and source mix monitoring.
Quick start endpoints: /v1/feed/stories, /v1/signals, /v1/storylines/search, /v1/briefings/latest.
For product access, see Pricing.